このアイテムのアクセス数: 48

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s13550-021-00752-3.pdf930.68 kBAdobe PDF見る/開く
タイトル: Increased [¹⁸F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors
著者: Shimizu, Yoichi  kyouindb  KAKEN_id
Nakai, Yukihiro
Watanabe, Hiroyuki  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-8873-1224 (unconfirmed)
Iikuni, Shimpei
Ono, Masahiro  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-2497-039X (unconfirmed)
Saji, Hideo
Kuge, Yuji
Saga, Tsuneo  KAKEN_id  orcid https://orcid.org/0000-0001-7801-9316 (unconfirmed)
Nakamoto, Yuji  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0001-5783-8048 (unconfirmed)
著者名の別形: 志水, 陽一
中井, 幸宏
渡邊, 裕之
飯國, 慎平
小野, 正博
佐治, 英郎
佐賀, 恒夫
中本, 裕士
キーワード: [¹⁸F]FMISO
Hypoxia
MRP1
発行日: 2021
出版者: Springer Nature
誌名: EJNMMI Research
巻: 11
論文番号: 9
抄録: BACKGROUND: [¹⁸F]Fluoromisonidazole ([¹⁸F]FMISO) is a PET imaging probe widely used for the detection of hypoxia. We previously reported that [¹⁸F]FMISO is metabolized to the glutathione conjugate of the reduced form in hypoxic cells. In addition, we found that the [¹⁸F]FMISO uptake level varied depending on the cellular glutathione conjugation and excretion ability such as enzyme activity of glutathione-S-transferase and expression levels of multidrug resistance-associated protein 1 (MRP1, an efflux transporter), in addition to the cellular hypoxic state. In this study, we evaluated whether MRP1 activity affected [¹⁸F]FMISO PET imaging. METHODS: FaDu human pharyngeal squamous cell carcinoma cells were pretreated with MRP1 inhibitors (cyclosporine A, lapatinib, or MK-571) for 1 h, incubated with [¹⁸F]FMISO for 4 h under hypoxia, and their radioactivity was then measured. FaDu tumor-bearing mice were intravenously injected with [¹⁸F]FMISO, and PET/CT images were acquired at 4 h post-injection (1st PET scan). Two days later, the same mice were pretreated with MRP1 inhibitors (cyclosporine A, lapatinib, or MK-571) for 1 h, and PET/CT images were acquired (2nd PET scan). RESULTS: FaDu cells pretreated with MRP1 inhibitors exhibited significantly higher radioactivity than those without inhibitor treatment (cyclosporine A: 6.91 ± 0.27, lapatinib: 10.03 ± 0.47, MK-571: 10.15 ± 0.44%dose/mg protein, p < 0.01). In the in vivo PET study, the SUVmean ratio in tumors [calculated as after treatment (2nd PET scan)/before treatment of MRP1 inhibitors (1st PET scan)] of the mice treated with MRP1 inhibitors was significantly higher than those of control mice (cyclosporine A: 2.6 ± 0.7, lapatinib: 2.2 ± 0.7, MK-571: 2.2 ± 0.7, control: 1.2 ± 0.2, p < 0.05). CONCLUSION: In this study, we revealed that MRP1 inhibitors increase [¹⁸F]FMISO accumulation in hypoxic cells. This suggests that [¹⁸F]FMISO-PET imaging is affected by MRP1 inhibitors independent of the hypoxic state.
著作権等: © The Author(s) 2021
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
URI: http://hdl.handle.net/2433/276405
DOI(出版社版): 10.1186/s13550-021-00752-3
PubMed ID: 33492449
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons